Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study. Issue 5 (28th May 2021)

• Record Type: Journal Article
• Authors: Vijiaratnam, Nirosen; Girges, Christine; Auld, Grace; Chau, Marisa; Maclagan, Kate; King, Alexa; Skene, Simon; Chowdhury, Kashfia; Hibbert, Steve; Morris, Huw; Limousin, Patricia; Athauda, Dilan; Carroll, Camille B; Hu, Michele T; Silverdale, Monty; Duncan, Gordon W; Chaudhuri, Ray; Lo, Christine; Del Din, Silvia; Yarnall, Alison J; Rochester, Lynn; Gibson, Rachel; Dickson, John; Hunter, Rachael; Libri, Vincenzo; Foltynie, Thomas
• Is Part Of: BMJ open. Volume 11:Issue 5(2021)
• Publication Date: 2021-05-28
• Subjects: Parkinson-s disease -- public health -- qualitative research; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-047993
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Parkinson's disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year. The aim of this multicentre UK trial is to confirm whether these previous positive results are maintained in a larger number of participants over 2 years and if effects accumulate with prolonged drug exposure. Methods and analysis: This is a phase 3, multicentre, double-blind, randomised, placebo-controlled trial of exenatide at a dose of 2 mg weekly in 200 participants with mild to moderate PD. Treatment duration is 96 weeks. Randomisation is 1:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48, 60, 72, 84 and 96 weeks. The primary outcome is the comparison of Movement Disorders Society Unified Parkinson's Disease Rating Scale part 3 motor subscore in the practically defined OFF medication state at 96 weeks between participants according to treatment allocation. Secondary outcomes will compare the change between groups among other motor, non-motor and cognitive scores. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups using a mixed model, adjusting for baseline scores. Secondary outcomes will be summarised between treatment groups using summary statistics and appropriate statistical tests to assess for significant differences. Ethics and dissemination: This trial has been approved by the South Central-Berkshire Research Ethics Committee and the Health Research Authority. Results will be disseminated in peer-reviewed journals, presented at scientific meetings and to patients in lay-summary format. Trial registration numbers: NCT04232969, ISRCTN14552789 .